indazoles has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 10 (83.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bang, EK; El-Damasy, AK; Jin, H; Keum, G; Seo, SH | 1 |
| Akula, S; Duyster, J; Kamasani, S; Kancha, RK; Manga, V; Sivan, SK; Vudem, DR | 1 |
| Chen, C; Ge, J; Hu, C; Hu, Z; Huang, T; Jiang, Z; Li, L; Liu, J; Liu, Q; Liu, X; Ren, T; Wang, A; Wang, B; Wang, J; Wang, L; Wang, W; Wu, H; Xia, R; Zhang, Y | 1 |
| Fu, J; Liang, L; Pan, X; Si, R; Sun, Y; Wang, J; Zhang, J; Zhang, Q | 1 |
| Chen, J; Cronin, CN; Johnson, E; Kallioniemi, O; Kontro, M; McTigue, M; Murray, BW; Pemovska, T; Porkka, K; Repasky, GA; Wells, P; Wennerberg, K | 1 |
| Chehab, F; Gunthorpe, M; Holmes, JP; Lasater, EA; Massi, ES; Politi, J; Sali, A; Shah, NP; Smith, CC; Stecula, A; Tan, SK | 1 |
| Deininger, MW; Druker, BJ; Eide, CA; O'Hare, T; Pomicter, AD; Savage, SL; Vellore, NA; Yan, D; Zabriskie, MS | 1 |
| Brummer, T; Dengjel, J; Ellermann, J; Gretzmeier, C; Halbach, S; Hu, Z; Wöhrle, FU | 1 |
| Amler, L; Deininger, MW; Eiring, AM; Guan, Y; Hampton, G; Lackner, M; Lu, S; O'Hare, T; Wagle, M; Wang, Y; Wongchenko, M; Yan, Y | 1 |
| Attkisson, E; Dai, Y; Grant, S; Jordan, N; Kolluri, N; Kramer, L; Muschen, M; Nguyen, N; Nguyen, T | 1 |
| Chen, ZP; Ju, HQ; Liu, JY; Liu, Z; Liu, ZH; Wang, SX; Wang, SY; Wang, YF; Xia, M; Xiang, YF; Xing, GW; Zeng, FL | 1 |
| Kibble, A; Shumoogam, J; Walker, K | 1 |
12 other study(ies) available for indazoles and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
Topics: Amination; Antineoplastic Agents; Cell Proliferation; Drug Design; Fusion Proteins, bcr-abl; Humans; Indazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation; Protein Kinase Inhibitors | 2020 |
Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors.
Topics: Axitinib; Computational Biology; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl | 2017 |
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants includi
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; Fusion Proteins, bcr-abl; Humans; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Mutation; Neoplasms, Experimental; Piperazines; Protein Kinase Inhibitors; Pyridines; Structure-Activity Relationship | 2018 |
Discovery of novel Bcr-Abl
Topics: Antineoplastic Agents; Benzamides; Binding Sites; Cell Proliferation; Drug Design; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation; Mutation; Piperazines; Pliability; Protein Binding; Protein Kinase Inhibitors | 2019 |
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Topics: Angiogenesis Inhibitors; Axitinib; Cell Line; Cell Proliferation; Crystallization; Crystallography, X-Ray; Drug Repositioning; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Molecular Conformation; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib.
Topics: Axitinib; Dasatinib; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imidazoles; In Vitro Techniques; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines | 2016 |
Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.
Topics: Axitinib; Fusion Proteins, bcr-abl; Humans; Imidazoles; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors | 2016 |
Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Topics: Adaptor Proteins, Signal Transducing; Axitinib; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imidazoles; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Niacinamide; Phenylurea Compounds; Point Mutation; Protein Interaction Maps; Protein Kinase Inhibitors; Sorafenib; src-Family Kinases | 2016 |
A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Topics: Apoptosis; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Drug Tolerance; Forkhead Box Protein O1; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Sulfonamides; Tumor Cells, Cultured | 2016 |
HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, SCID; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Xenograft Model Antitumor Assays | 2011 |
BJ-B11, a novel Hsp90 inhibitor, induces apoptosis in human chronic myeloid leukemia K562 cells through the mitochondria-dependent pathway.
Topics: Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; bcl-X Protein; Benzamides; Caspases; Cell Survival; G1 Phase; HSP90 Heat-Shock Proteins; Humans; Indazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Proto-Oncogene Proteins c-akt; Resting Phase, Cell Cycle; Signal Transduction | 2011 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 4.
Topics: Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Biomedical Research; CA-125 Antigen; Clinical Trials as Topic; Dasatinib; Female; Humans; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Neoplasms; Ovarian Neoplasms; Pyrimidines; Snake Venoms; Sulfonamides; Thiazoles; Treatment Outcome | 2007 |